234 related articles for article (PubMed ID: 31592646)
1. Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets.
Skok Ž; Zidar N; Kikelj D; Ilaš J
J Med Chem; 2020 Feb; 63(3):884-904. PubMed ID: 31592646
[TBL] [Abstract][Full Text] [Related]
2. Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
Kashyap M; Kandekar S; Baviskar AT; Das D; Preet R; Mohapatra P; Satapathy SR; Siddharth S; Guchhait SK; Kundu CN; Banerjee UC
Bioorg Med Chem Lett; 2013 Feb; 23(4):934-8. PubMed ID: 23321564
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition.
Yi JM; Zhang XF; Huan XJ; Song SS; Wang W; Tian QT; Sun YM; Chen Y; Ding J; Wang YQ; Yang CH; Miao ZH
Oncotarget; 2015 Apr; 6(11):8960-73. PubMed ID: 25840421
[TBL] [Abstract][Full Text] [Related]
4. Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs.
Baglini E; Salerno S; Barresi E; Robello M; Da Settimo F; Taliani S; Marini AM
Eur J Pharm Sci; 2021 Jan; 156():105594. PubMed ID: 33059042
[TBL] [Abstract][Full Text] [Related]
5. Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy.
Bailly C
Chem Rev; 2012 Jul; 112(7):3611-40. PubMed ID: 22397403
[No Abstract] [Full Text] [Related]
6. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
Chen W; Qiu J; Shen YM
Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
8. Recent developments of DNA poisons--human DNA topoisomerase IIα inhibitors--as anticancer agents.
Pogorelčnik B; Perdih A; Solmajer T
Curr Pharm Des; 2013; 19(13):2474-88. PubMed ID: 23363399
[TBL] [Abstract][Full Text] [Related]
9. A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents.
Okoro CO; Fatoki TH
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768852
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerases as anticancer targets.
Delgado JL; Hsieh CM; Chan NL; Hiasa H
Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
[TBL] [Abstract][Full Text] [Related]
11. Discovery of new ATP-competitive inhibitors of human DNA topoisomerase IIα through screening of bacterial topoisomerase inhibitors.
Skok Ž; Durcik M; Gramec Skledar D; Barančoková M; Peterlin Mašič L; Tomašič T; Zega A; Kikelj D; Zidar N; Ilaš J
Bioorg Chem; 2020 Sep; 102():104049. PubMed ID: 32688116
[TBL] [Abstract][Full Text] [Related]
12. Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90.
Lee MG; Liu YC; Lee YL; El-Shazly M; Lai KH; Shih SP; Ke SC; Hong MC; Du YC; Yang JC; Sung PJ; Wen ZH; Lu MC
Mar Drugs; 2018 Jun; 16(6):. PubMed ID: 29890785
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy.
Chikamori K; Grozav AG; Kozuki T; Grabowski D; Ganapathi R; Ganapathi MK
Curr Cancer Drug Targets; 2010 Nov; 10(7):758-71. PubMed ID: 20578986
[TBL] [Abstract][Full Text] [Related]
14. Alchemix, p53 and topoisomerase.
Grand RJ; Stewart GS
Aging (Albany NY); 2015 Sep; 7(9):601-2. PubMed ID: 26388618
[No Abstract] [Full Text] [Related]
15. Identification of potent virtual leads and ADME prediction of isoxazolidine podophyllotoxin derivatives as topoisomerase II and tubulin inhibitors.
Bkhaitan MM; Mirza AZ; Shamshad H; Ali HI
J Mol Graph Model; 2017 May; 73():74-93. PubMed ID: 28242581
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage.
Barker CR; McNamara AV; Rackstraw SA; Nelson DE; White MR; Watson AJ; Jenkins JR
Nucleic Acids Res; 2006; 34(4):1148-57. PubMed ID: 16504968
[TBL] [Abstract][Full Text] [Related]
17. Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
Park S; Thapa Magar TB; Kadayat TM; Lee HJ; Bist G; Shrestha A; Lee ES; Kwon Y
Eur J Med Chem; 2017 Feb; 127():318-333. PubMed ID: 28068603
[TBL] [Abstract][Full Text] [Related]
18. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
Yamashita M; Tahara T; Hayakawa S; Matsumoto H; Wada SI; Tomioka K; Iida A
Bioorg Med Chem; 2018 May; 26(8):1920-1928. PubMed ID: 29519604
[TBL] [Abstract][Full Text] [Related]
20. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
Pan X; Hartley JM; Hartley JA; White KN; Wang Z; Bligh SW
Phytomedicine; 2012 May; 19(7):618-24. PubMed ID: 22402246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
